Mismatch Repair Proficient (pMMR)
1 drugsPredictive biomarker for patient selection in 5 indications
1
Approved Drugs
5
Indications
1
Companies
Mismatch Repair Proficient (pMMR) is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 5 indications including Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer, Advanced renal cell carcinoma (first-line, in combination with pembrolizumab), Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus). Explore the targeted therapies, indications, testing methods, and companies developing Mismatch Repair Proficient (pMMR) drugs below.
Search Mismatch Repair Proficient (pMMR) Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting Mismatch Repair Proficient (pMMR)
| Drug | Company | Therapeutic Area |
|---|---|---|
| LENVIMA | EISAI INC | Oncology |
Mismatch Repair Proficient (pMMR) Indications
Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Advanced renal cell carcinoma (first-line, in combination with pembrolizumab) Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus) Unresectable hepatocellular carcinoma (first-line) Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)